Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Sign up today!
The appeals court's decision overturned part of a lower court ruling that would have revoked the Food and Drug Administration's 23-year-old approval of mifepristone.
The closely watched case is likely to wind up at the U.S. Supreme Court, which already intervened to keep mifepristone available while the legal fight winds through the courts.
The closely watched case is likely to wind up at the U.S. Supreme Court, which already intervened to keep mifepristone available while the legal fight winds through the courts.